title: Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.
abstract: Activation of kit-receptor tyrosine kinase occurs in all cases of gastrointestinal stromal tumors, regardless of the mutation status of kit. Imatinib mesylate (STI 571,Gleevec) is a selective inhibitor of certain protein tyrosine kinases. It has been shown in preclinical models and clinical studies to have activity against such tumors. The aim of the present study was to report the efficacy of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors. Two adults with histologically confirmed, unresectable, and metastatic gastrointestinal stromal tumors that expressed CD117 (a marker of kit-receptor tyrosine kinase) were identified at our institution during 2000-2002. As the diseases were advanced and not amenable to surgery, chemotherapy, or radiation therapy, imatinib mesylate was used, because this targeted inhibitor has been shown to be active against advanced gastrointestinal stromal tumors and has a mild toxicity profile. Imatinib mesylate induced a sustained response in both patients with advanced unresectable or metastatic gastrointestinal stromal tumors. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
authors.affiliation: Howard University Hospital, Washington, DC 20059, USA. syedphasan@hotmail.com
authors.forename: Syed
authors.initials: S
authors.lastname: Hasan
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hassan
authors.forename: Luc
authors.initials: L
authors.lastname: Oke
authors.forename: Kimberly
authors.initials: K
authors.lastname: Dinh
authors.forename: Gladys
authors.initials: G
authors.lastname: Onojobi
authors.forename: Fred
authors.initials: F
authors.lastname: Lombardo
authors.forename: Fitzroy
authors.initials: F
authors.lastname: Dawkins
authors.forename: Momodu
authors.initials: M
authors.lastname: Jack
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D044383:Black People; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D017154:Stromal Cells / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases